40 results about "Preclinical research" patented technology

The invention relates to a touch fluid neuron specific tracing imaging agent, a preparation method and application, and belongs to the technical field of nuclear medicine imaging, the tracing imaging agent is composed of a nerve tracer agent horseradish peroxidase (HRP), zirconium-89 isotope chelated by deferoxamine and a pharmaceutically acceptable carrier, the effective tracking window of the tracer agent is prolonged to 120 hours, and the effective tracking window of the tracer agent is prolonged to 120 hours. The multi-stage synaptic transfer period of the fluid touching neuron can be completely covered; the spatial resolution is improved by 5-8 times compared with that of traditional FDG-PET, and a fluid touching neuron cluster can be accurately presented; the in-vitro serum stability is excellent, the radiochemical purity is still larger than or equal to 80.5% within 120 hours, PET / MRI bimodal imaging can be adapted, drug administration is conducted through lateral ventricle minimally invasive injection, the probe is suitable for various animal models such as mice, rats and non-human primates, in-vivo dynamic tracing of sympathetic fluid neuron trans-synapses can be achieved on the premise that no tissue damage exists, and the probe has a good application prospect. And a key technical tool is provided for neural circuit analysis, neuroscience basic research and preclinical research of neurodegenerative diseases.

The invention relates to the field of vaccines, in particular to application of a bacillus calmette-guerin vaccine and a complete freund's adjuvant in preparation of tuberculosis prevention vaccines. The invention provides a novel inoculation strategy of subcutaneous combined inoculation of the bacillus calmette guerin vaccine and the complete freund's adjuvant, the safety consistent with that of the existing tuberculosis prevention vaccine in the clinical stage is achieved, and the immune protection effect higher than that of the existing tuberculosis prevention vaccine in the clinical stage and the preclinical research stage is achieved. The compound is expected to be used as a novel tuberculosis vaccine for preventing tuberculosis.

The invention relates to the technical field of medicines, in particular to application of aspiramycin and / or imiquimod in preparation of a medicine for treating VACV. Aspiramycin and imiquimod which are screened from medicines on the market have antiviral activity, and experimental data show that the Aspiramycin and the imiquimod have anti-VACV medicine activity. Aspiramycin and imiquimod (especially combined application) are used for preparing the medicine for treating VACV, so that the time and cost of preclinical research can be greatly reduced. As the action mechanism of the pox viruses is not unique to the VACV, the combined strategy has the potential to be expanded to infection treatment of other pox viruses (such as monkey pox virus MPXV) and even other DNA (Deoxyribose Nucleic Acid) viruses.

The invention provides a preparation method of a polymer nanorod with a controllable and adjustable length-diameter ratio. The invention further provides a preparation method of the anti-tumor nano-drug, the anti-tumor nano-drug is prepared by the preparation method of the polymer nano-rod with the controllable and adjustable length-diameter ratio, and the paclitaxel nano-drug is prepared by the method. The three-step method adopted by the invention is based on a traditional emulsification method, special instruments and equipment are not needed, large-scale production is easy to realize, and the batch yield is relatively high; the preparation conditions are mild, and the drug activity can be effectively protected; the method is low in energy consumption, economical and efficient. According to the method, the length-diameter ratio of the nanorod can be controllably adjusted on the basis of not changing the raw material composition of the nanorod, the consistency of other parameters in the subsequent biological behavior research is favorably kept, the influence of mixed factors is reduced, and the reliability and repeatability of the research can be improved. Besides, when the length-diameter ratio of the nano-carrier is adjusted, only the process of heating fracture in the last step needs to be changed, so that the cost can be greatly saved, customized production is facilitated, or preclinical simple preparation is realized.

The invention discloses a traditional Chinese medicine composition for resisting ovarian cancer and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine is characterized by being prepared from the following raw materials in parts by weight: 30 parts of astragalus membranaceus, 9 parts of dandelion, 9 parts of cyrtomium fortunei, 9 parts of sanguisorba officinalis, 9 parts of pericarpium citri reticulatae, 9 parts of honeysuckle, 9 parts of ginseng, 9 parts of cirsium japonicum, 9 parts of herba cepbalanoplosis segeti, 15 parts of longan aril, 15 parts of radix rehmanniae, 15 parts of eucommia ulmoides and 6 parts of pseudo-ginseng. The invention not only proves the phenotypic effects of the tonifying and cancer eliminating decoction for inhibiting the proliferation and migration of ovarian cancer cells and inducing apoptosis, but also finds that the effect of the tonifying and cancer eliminating decoction is closely related to the activation of inhibiting a PI3K-AKT signal channel for the first time, the scientific connotation of the tonifying and cancer eliminating decoction is clarified from the molecular level, and an important preclinical research foundation is laid for developing the tonifying and cancer eliminating decoction into a modern new traditional Chinese medicine for resisting ovarian cancer.

The application discloses a kind of fast high signal-to-noise ratio CEST quantification parameter map calculation methods based on K-means clustering, method includes: according to the pixel number and standard deviation of CEST-MRI image Setting clustering termination condition;K-means clustering is carried out to the target to be clustered, and the average Z spectrum of each class is fitted respectively;For the class that does not meet the condition, the class is taken as the target to be clustered, and the fitting parameter of the average Z spectrum of the class is taken as the initial value of fitting after next clustering, turn to clustering step;For the class that meets, the fitting value of the class is taken as the quantification signal output of all pixels in the class, and when all classes meet the clustering termination condition, the fitting value of all classes is output based on class fitting Quantification map according to the fitting value of all classes.The method can improve the signal-to-noise ratio and fitting accuracy of CEST-MRI quantification map and significantly reduce the calculation time, which is beneficial to the promotion and application in preclinical research and clinical practice.

This invention discloses a method for constructing lung organoids with spontaneous vascularization and branching morphology. By optimizing the culture protocol and progressively inducing directional mesoderm, vascularized foregut endoderm, vascularized lung bud organoids, and vascularized lung organoids, lung organoids with both vascularization and branching morphology are successfully cultured, thus more realistically simulating the structural characteristics of the human lung. This invention has significant advantages: First, it can effectively induce the formation of vascularization and branching structures in lung organoids, overcoming the shortcomings of traditional lung organoids that lack vascularization and branching structures; second, by adjusting the culture method in the early stages, the uniformity of the lung organoids is significantly improved, enhancing the reliability and reproducibility of experimental results. This invention provides a more precise and efficient experimental platform for preclinical studies such as lung disease research, drug screening, and toxicology testing, and has significant application value.

Provided is a universal preclinical bio-distribution detection kit for NK cell therapy products. The present invention further relates to specific use of a gene sequence set forth in SEQ ID No. 1 in distinguishing a human NK cell gene from a non-human animal gene. By means of providing a specific DNA sequence, a DNA sequence derived from the human NK cell can be specifically distinguished from a DNA sequence derived from the non-human animal gene, and based on the specific DNA sequence, a qPCR system for distinguishing the human NK cell gene from the non-human animal gene is constructed, providing a primer pair and a probe set for NK cells and derivative cell therapy products thereof. In addition, a universal preclinical bio-distribution detection kit for the NK cell therapy products is successfully designed, thereby providing convenience for the preclinical research on the NK cells and derivative cell therapy products thereof.

The invention relates to the technical field of biomedicine, and discloses an experimental method for treating osteomyelitis by using human umbilical cord mesenchymal stem cells. The method aims at solving the problems that an existing osteomyelitis experimental model is disjointed from clinical pathological characteristics, the activity loss of mesenchymal stem cells in an infection environment is large, a combined intervention scheme lacks pathological suitability, and an evaluation system is single. The method comprises the following steps: firstly, constructing a clinical adaptive model by combining pathogenic bacterium injection with immunosuppression and ischemia induction, then carrying out anti-oxidation and targeted colonization double pretreatment on MSC, then implementing stepped combined intervention according to the requirements of acute-stage bacterium control and chronic-stage repair, and comprehensively evaluating through infection control, immune balance and bone repair multi-dimensional indexes, so as to obtain a bone repair model. The constructed model is closer to clinical pathological characteristics, the MSC activity and colonization ability are stable, the intervention scheme collaboration is high, the evaluation result is comprehensive and reliable, a standardized tool can be provided for preclinical research of osteomyelitis treatment schemes, and the conversion guidance value of the experimental result is improved.

Cannabinoids are a promising and potent class of agents in the management of pain, and preclinical studies in rodent models suggest that cannabinoids may be particularly potent in relieving neuropathic pain. Despite the potential benefits and value of cannabinoids, clinical acceptance has been limited due to CNS side effects at systemic analgesic doses and the fear of misuse potential. What is needed are novel cannabinoid-acting compositions and methods for treating pain. The present disclosure relates to compositions targeting cannabinoid receptors and uses thereof for treating, preventing, and / or mitigating pain.

This invention discloses the application of total flavonoids from sea buckthorn leaves in the preparation of drugs for treating ulcerative colitis, relating to the pharmaceutical field. Animal experiments of this invention have demonstrated that total flavonoids from sea buckthorn leaves can effectively alleviate clinical symptoms and pathological damage of ulcerative colitis; improve intestinal barrier damage in mice with ulcerative colitis; improve the inflammatory response in mice with ulcerative colitis; improve the decreased secretion of short-chain fatty acids in mice with ulcerative colitis; and regulate the abundance and structure of intestinal flora in mice with ulcerative colitis. It shows promise for developing new anti-ulcerative colitis drugs. Therefore, sea buckthorn leaves can be transformed from waste into a valuable resource, providing solid preclinical research evidence for the subsequent development of special medical foods, health products, or functional teas with sea buckthorn leaf flavonoids as the core component, offering daily nutritional support and disease management for patients with ulcerative colitis.

The invention relates to a skin-like chip simulation platform based on a microfluidic technology. The skin-like chip simulation platform sequentially comprises a skin-like layer, a skin-like layer, a cytoplasm matrix simulation layer and an interstitial fluid circulation layer from top to bottom, a hole array is arranged on the imitated skin layer; an interstitial fluid enrichment cavity communicated with the hole array is formed in the simulated cortex, and the interstitial fluid enrichment cavity is provided with an enrichment outlet and an enrichment inlet; an interstitial fluid micro-channel is arranged in the cytoplasm matrix simulation layer, one end of the interstitial fluid micro-channel is communicated to the enrichment inlet, and the other end of the interstitial fluid micro-channel is communicated to the interstitial fluid flowing layer; an interstitial fluid storage cavity is formed in the interstitial fluid circulation layer and is provided with a storage cavity outlet and a storage cavity inlet; the device further comprises an interstitial fluid circulation channel. The skin-like chip simulation platform designed by the invention can accurately simulate the human skin environment, provides a simulation test platform for novel extraction electrode design, parameter optimization and safety evaluation of a counter ion electroosmosis technology, and remarkably reduces the preclinical research risk and cost of new technology development.

The present application belongs to the technical field of tumor detection and cell separation, and particularly relates to a kit for separating and recovering after immunocapture of circulating tumor cells, a preparation method and application. The kit comprises an immunocapture module, a dissociation and recovery module, a cell protection module and elution and supplement factor solutions. The immunocapture module adopts magnetic microspheres modified by double antibody fusion proteins, can recognize multiple markers such as EpCAM and Vimentin, and realizes efficient capture of heterogeneous CTCs. The dissociation and recovery module uses a low-temperature buffer system and a cleavable cross-linking agent to release cells gently. The cell protection module maintains the integrity and activity of the cell membrane during the separation process. The method of the present application can ensure the capture efficiency while obtaining high-activity CTCs, and is suitable for single-cell sequencing, drug sensitivity analysis, organoid culture and patient-derived cell line construction and other preclinical research.

The invention discloses preparation and application of a micromolecular nano modifier for enhancing active targeting. The preparation method comprises the following steps: synthesizing a micromolecular double-target affinity agent GLM; the preparation method comprises the following steps: grafting a micromolecular double-target affinity agent GLM to a side chain of PEG to obtain PEG-GLM; and modifying the PEG-GLM onto the surfaces of the porphyrin-based metal organic framework PCN-224 nano particles, so as to obtain the polyethylene glycol-micromolecule co-modified nano material. According to the invention, a high-affinity micromolecular nano-material GLM aiming at VEGFR (vascular endothelial growth factor receptor) and PDGFR (PDGFR) double targets is synthesized and is grafted to PEG (polyethylene glycol). After the synthesized GLM-PEG is modified on the nano material PCN-224, a cellular uptake experiment and an in-vivo fluorescence imaging experiment jointly verify that the nano material has excellent capability of actively targeting liver cancer from a cellular level and an animal level. The follow-up preclinical research and clinical transformation are expected to be carried out.

The application relates to the technical field of antibodies, in particular to a novel coronavirus Omicron mutant specific antibody and application thereof. The application provides an antibody specifically combined with the novel coronavirus Omicron mutant, the antibody can be used as a specific antibody for antigen detection of the Omicron mutant, is used for identification of a novel coronavirus vaccine designed for the Omicron mutant, and is used for quantitative detection of the content of Spike RBD protein expressed by the vaccine, or is used for quality control of a novel coronavirus vaccine and immunogenicity detection of clinical and preclinical research, or is used as a quality control antibody for detection of protective antibodies in serum after vaccination.

The application belongs to the field of biological medicine, and particularly relates to a Bama pig model for preclinical research of a weight loss drug COST and application. Healthy Bama pigs are first adaptively fed with ordinary feed, and then fed with high-fat feed to model, and the Bama pigs are detected for obesity-related indexes at a fixed time period every week; the high-fat feed comprises ordinary feed, beef tallow, artificial butter, sucrose, casein, experimental animal premix, microcrystalline cellulose, calcium bicarbonate, gypenoside, peppermint leaf, maslinic acid, ursolic acid, atractylodes, nutmeg. The application can quickly construct a Bama pig model with stable phenotype, and provides a reliable model for preclinical research of a new drug for treating obesity, and provides guarantee for research on the mechanism of obesity, screening, development and mechanism research of a new drug for treating obesity and the like.

A radiolucent fixation system is provided for orthopedic and translational applications, comprising implantable thermoplastic plates, rods, and fasteners for stabilizing fractures or bone defects while enabling clear diagnostic imaging. The fasteners include a rigid central component and deformable malleable grip segments that are selectively welded or staked using an energy-producing handheld device. In some embodiments, blind-end rivet mechanisms are used to secure fixation where access to the distal cortex is limited. The radiolucent materials reduce imaging artifacts, enable repeated longitudinal studies in preclinical research, and avoid complications associated with metal implants such as stress shielding and imaging interference. Methods for device implantation, imaging, and fabrication using additive and subtractive manufacturing are also described.

The invention discloses preparation and application of a nuclide-photodynamic synergistic metal organic framework material. The method comprises the following steps: synthesizing nano-particles Zr-MOF with the diameter of 50-70nm; and carrying out radionuclide 177Lu labeling on Zr-MOF, thereby obtaining the product. According to the invention, the ROS generation capability of the gene is also inspected, and the tumor killing capability and ICD induction capability of the gene are verified on the cellular level. A preclinical research shows that the marking rate of 177Lu-Zr-MOF is greater than 95%, and the 177Lu-Zr-MOF has good stability within 24 h and has good ROS generation induction capability under 660 nm illumination. Meanwhile, the polypeptide has a remarkable tumor killing effect and capability of inducing DAMPs release, and is expected to be subsequently subjected to preclinical research and clinical transformation.

This invention discloses the application of Huanglian Shangqing tablets combined with glucocorticoids in the preparation of drugs for treating leukemia. The Huanglian Shangqing tablets combined with glucocorticoids can inhibit the activity of Jurkat cells in a concentration-dependent manner; inhibit the proliferation of Jurkat cells in a concentration- and time-dependent manner; and significantly induce apoptosis in the human acute lymphoblastic leukemia cell line Jurkat. In animal experiments, compared with the model group, the Huanglian Shangqing tablets combined with glucocorticoids can increase the hematocrit ratio of leukemia mice, reduce the spleen burden in mice, have no obvious toxic side effects, and improve the survival rate of leukemia mice. Therefore, the Huanglian Shangqing tablets combined with glucocorticoids have the potential value of developing drugs to reverse glucocorticoid resistance in leukemia. Furthermore, Huanglian Shangqing tablets are already used clinically, which can effectively shorten the preclinical research period and has a very good application prospect.

The invention discloses a synthetic method of an androgen receptor N-terminal domain (AR NTD) inhibitor, namely, Raaniten triacetate (EPI-506), and relates to a synthetic method of the Raaniten triacetate (EPI-506). The preparation method comprises the following steps: firstly, preparing high-purity bisphenol A disodium salt by taking bisphenol A as an initial raw material; the preparation method comprises the following steps: reacting bisphenol A disodium salt with (R)-p-toluenesulfonic acid-2, 2-dimethyl-1, 3-dioxolanyl-4-methyl ester and (R)-p-toluenesulfonic acid glycidyl ester in sequence, and carrying out catalytic reflux ring opening to obtain an intermediate Raanite (EPI-002); and reacting the intermediate with acetyl chloride, triethylamine and 4-dimethylaminopyridine to obtain a target product EPI-506. The synthesis method disclosed by the invention is simple in process, mild in operation condition and relatively high in yield, and provides reliable technical support for preclinical research, process amplification and industrial application of the EPI-506.

The invention belongs to the technical field of cell culture, and particularly relates to a culture method and application of human perinervous cells. The culture method comprises the following steps: inoculating HBVP into a compound basic culture medium which is prepared from DMEM and MCDB 131 mixed in a ratio of 1: 1, accurately adding HEPES with the final concentration of 10 mM, 1% (v / v) Glutamax, 1% (v / v) N2, 1% (v / v) G-5, 1% (v / v) B-27, 10 ng / mL hEGF, 5% (v / v) fetal calf serum and 1% (v / v) penicillin-streptomycin into the compound basic culture medium to form a special HBVP culture solution, and the culture solution can provide an optimal growth microenvironment for HBVP. The cell culture medium can effectively promote continuous and stable proliferation of cells and maintain high activity, can be used as a high-quality cell source for HBVP related basic research, preclinical research and potential application, and has good practicability and popularization value.

The invention belongs to the technical field of tumor detection and cell separation, and particularly relates to a kit for separating and recycling circulating tumor cells after immunocapture, a preparation method and application. The kit comprises an immunocapture module, a dissociation recovery module, a cell protection module and an elution and supplement factor solution, the immunocapture module adopts magnetic microspheres modified by double-antibody fusion protein and can simultaneously recognize various markers such as EpCAM and Vimentin, and efficient capture of heterogeneity CTCs is achieved; the dissociation and recovery module gently releases cells by using a low-temperature buffer system and a cleavable cross-linking agent; the cell protection module maintains the integrity and activity of cell membranes in the separation process. According to the method, the high-activity CTCs can be obtained while the capture efficiency is guaranteed, and the method is suitable for scientific research and preclinical research such as single cell sequencing, drug sensitivity analysis, organoid culture and patient-derived cell line construction.

The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a culture medium for inducing mesenchymal cells to differentiate into insulin-secreting cells and application of the culture medium. By accurately regulating and controlling the oxidation-reduction state of NAD < + > / NADH in cells, the composition proportion of exogenous fatty acid, the dynamic supply concentration of glucose and the anti-oxidative stress level, the differentiation efficiency is remarkably improved, the induction period is shortened, and the method is suitable for industrial production on the premise of not depending on recombinant protein induction factors such as Activin A and Wnt3a. And a mature beta-like cell with stable glucose stimulus dependent insulin secretion (GSIS) capability is obtained. The kit is especially suitable for human adipose tissue-derived mesenchymal stem cells, and can be used as an independent kit product for preclinical research and drug screening of diabetes cell replacement therapy.

The invention belongs to the field of biological culture, and particularly relates to a continuous cell culture method and application thereof in continuous culture of animal cells, and the method specifically comprises the following steps: after cells are recovered and amplified, placing the cells in a bioreactor for a first cycle of continuous cycle production; after the first circulation is finished, part of cells are harvested from the bioreactor and used for preparing a finished product, then a fresh culture medium is supplemented into the bioreactor for continuous culture, and the circulation is repeated. By the adoption of the technical scheme, the harvested cells have good uniformity and stability, and the requirements for the number and quality of the cells for preclinical research can be met in the preclinical research stage. And the continuous production does not additionally consume disposable reaction bag consumables, so that the production period is shortened, the cost is reduced, the yield is greatly improved, and the large-scale production of cell therapy products is realized.

This disclosure relates to Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3), an autosomal dominant neurodegenerative disorder caused by excessive repetition of the polyglutamine-coding region in the ataxia protein-3 (ATXN3) gene. The extended ATXN3 readily aggregates and interferes with multiple cellular systems, ultimately leading to cellular dysfunction and death in specific neuronal populations. To date, no treatments have been developed that can reverse or delay the progression of MJD / SCA3. Strategies based on inhibiting harmful gene products have shown promising results in preclinical studies. However, these strategies do not target the root cause of the disease, producing incomplete and / or transient therapeutic effects in target cells or tissues. Recently, gene-based therapies, including the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system for gene editing, have been successfully used to permanently inactivate and correct disease-related genes, offering hope for the development of curative therapies for hereditary diseases.

The invention discloses an application of a diarrhea stopping capsule in preparation of a medicine for treating leukemia, the diarrhea stopping capsule can inhibit proliferation of leukemia cells HEL, KG-1a, K562 and Jurkat, and the inhibition effect on the cells HEL is dose-dependent and time-dependent; the drug-containing serum of the Xiaoshui capsule blocks the cell cycle of human erythroleukemia cells HEL in the G1 phase, and can obviously induce apoptosis of the human erythroleukemia cells HEL. Furthermore, in-vivo experiments show that low, medium and high dosages of the Xiaoshui capsules have no influence on liver and kidney functions of mice; the diarrhea stopping capsule can reduce the weight of the spleen of a mouse with leukemia, increase the hemolysis-to-solution ratio, improve the spleen structure, reduce the expression of a CD71 + cell population, promote differentiation of the spleen and immature red blood cells of bone marrow to a Ter119 + cell population and recover the spleen structure of the mouse. The Xiaoshui capsule is a clinical Miao medicine, can effectively shorten the preclinical research, and has a good application prospect in preparation of medicines for treating myelogenous and lymphatic leukemia.

A machine for washing and / or sanitizing articles, applied in the chemical, pharmaceutical and / or clinical / preclinical research field, comprises: a cabinet (10) defining a treatment chamber (20) having at least one access opening (30); a door (40) associated with said access opening (30) and controllable between a closed condition, in which it closes said access opening (30), and an open condition, in which it does not close said access opening (30); an inflatable gasket (50) extending along the perimeter of said door (40), controllable between an inflated configuration, in which it creates a sealing closure when said door (40) is in the closed condition, and a deflated configuration; at least one latch (60) controllable between an active condition, in which it locks said door (40) in the closed condition, and a rest condition, in which it does not exert a locking action; a pneumatic circuit (100) acting on said inflatable gasket (50) to bring it into the inflated configuration. Said at least one latch (60) houses a portion of said pneumatic circuit (100).

The invention relates to an AAV (adeno-associated virus) virus for knocking down CTH (cytidylcholine) in targeted hepatocytes and application thereof, which adopts an adeno-associated virus vector system driven by a TBG promoter to realize specific CTH gene knocking down of the hepatocytes through caudal vein injection. Experiments prove that the targeted knock-down hepatocyte CTH can significantly improve the liver function index of an OC mouse model, relieve inflammatory response and reverse the fibrosis process. The key regulation and control effect of the CTH gene in the OC process is disclosed for the first time, an ideal preclinical research model is provided for developing a CTH-targeted OC treatment medicine, and the application has important application value in the aspect of improving the prognosis of a patient.

The invention relates to a snake venom capsule for treating alopecia, which aims at the problems that the alopecia is complicated in pathogenesis and the existing treatment method is limited, takes agkistrodon acutus venom, trimeresurus venom and cobra venom as main active ingredients, and is matched with 17 traditional Chinese medicines such as polygonum multiflorum, prepared rehmannia root, semen cuscutae and the like. The snake venom is treated by adopting an ultralow-temperature freeze-drying technology, the retention rate of active enzyme is ensured to be greater than or equal to 90%, and the capsule is prepared through the steps of raw material treatment, scientific compatibility and mixing, a granulation process, capsule filling and the like. The capsule accurately activates hair follicle stem cells in a targeted manner through snake venom active enzyme, promotes hair follicle microangiogenesis, forms an activation-flow increasing-anti-inflammatory-hair consolidation closed-loop treatment system with a traditional Chinese medicine formula, can effectively treat alopecia, preclinical research shows that the hair density of a patient is averagely increased by 45%-65% after the patient continuously takes the capsule for 3 months, and the capsule does not have obvious liver and kidney toxic reaction and has a good treatment effect on alopecia. A safe, efficient and economical treatment choice is provided for alopecia patients.